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Nolatrexed dihydrochloride (AG337, THYMITAQTM; Agouron
Pharmaceuticals, Inc., San Diego, CA; Figure 1) is a novel folate-
based inhibitor of thymidylate synthase (TS; EC 2.1.1.45). TS
catalyses the terminal, rate limiting step of the de novo synthesis
of thymidine nucleotides and thymidine nucleotides are used
exclusively in the synthesis of DNA. TS is therefore an important
target for antiproliferative cancer chemotherapy (Touroutoglou
and Pazdur, 1996), and a number of classical antifolate TS
inhibitors have been developed which have demonstrated activity
in clinical trials in adults (Jackman and Calvert, 1995; Rustum et
al, 1997). The α and  γ glutamate carboxyl groups of classical
antifolates, such as raltitrexed (an inhibitor of TS) and
methotrexate (MTX), are negatively charged at physiological pH
and thus require carrier mediated uptake for entry into cells
(Goldman et al, 1968; Jansen et al, 1993). Once inside the cell,
classical antifolates can undergo polyglutamation in a reaction
catalysed by folylpolyglutamate synthetase (FPGS), which
involves the addition of further glutamate residues at the γ -
carboxyl position of the glutamate moiety (McGuire et al, 1980).
Polyglutamation enhances the intracellular retention and potency
of classical antifolates against target enzymes such as TS (Allegra
et al, 1985; Ward et al, 1992). However, resistance due to reduced
cellular uptake or reduced formation of intracellular polygluta-
mates may limit the clinical activity of classical antifolate drugs.
For example, the ability of lymphoblasts to metabolize MTX to
long-chain polyglutamate forms may be an important determinant
of the sensitivity childhood ALL to methotrexate-based therapy
(Whitehead et al, 1992; Masson et al, 1996), and acquired resist-
ance to MTX may be mediated by reduced transport and increased
expression of dihydrofolate reductase (Gorlick et al, 1997).
Nolatrexed, which as a nonclassical antifolate does not possess a
terminal glutamate moiety, was rationally designed using X-ray
crystallographic techniques (Webber et al, 1993) to overcome
resistance to classical antifolates as a result of reduced uptake and
polyglutamation. 
Nolatrexed is a non-competitive TS inhibitor with an inhibition
constant of 11 nM, with activity against rodent and human tumour
cell lines in vitro, and against selected tumour models in vivo
(Webber et al, 1996). Phase I studies in adults of nolatrexed
administered either as a 5-day continuous infusion (Rafi et al,
1995), or orally every 6 hours for 5 days (Rafi et al, 1996), demon-
strated dose-limiting myelosuppression with oral mucositis and a
recommended Phase II dose of 800 mg/m2 24 h− 1. Evidence of
clinical activity was observed when nolatrexed was administered
as a 5 day intravenous infusion in Phase II studies in adults with
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carcinoma of the head and neck (Belani et al, 1997). 
To facilitate the rational introduction of nolatrexed into paedi-
atric oncology practice, a Phase I study was performed. The aims
of this Phase I study were to determine the maximally tolerated
dose (MTD), dose-limiting toxicities and pharmacokinetics of
nolatrexed, administered as a 5-day continuous intravenous infu-
sion in children with advanced malignancy. In addition, evidence
of TS inhibition was sought, by measurement of plasma UdR, and
the plasma concentrations of nolatrexed associated with toxicity,
efficacy and TS inhibition determined. 
METHODS 
Patient eligibility 
The study was open from September 1995 until April 1998.
Patients aged less than 18 years with histologically proven malig-
nancy, including acute leukaemia and solid tumours involving the
bone marrow, and for whom no conventional therapies were
appropriate, were eligible. Patients were required to have a Lansky
Performance Scale score of ≥ 30 (Lansky et al, 1987), but children
were ineligible if they were a poor medical risk because of non-
malignant systemic disease or uncontrolled infection, or had
received chemotherapy or biologic therapy within 4 weeks of
receiving nolatrexed. In cases of acute leukaemia which were
refractory to chemotherapy, nolatrexed could be administered
within 4 weeks of prior therapy, provided any toxicity associated
with the previous treatment had resolved. Patients who had
received radiation therapy within 6 weeks of receiving nolatrexed,
or had concurrent malignancies at other sites were ineligible. 
Laboratory investigations were performed within the 14 day
period prior to the first dose of nolatrexed in order to ensure
adequate haematological (Hb >9 g dl− 1, neutrophil count
>1 × 109l − 1, platelet count >100× 109l − 1), renal (serum creatinine
≤ 1.5 × the upper limit of laboratory normal for age) and hepatic
(serum total bilirubin within the upper limit of laboratory normal,
aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2
times the upper limit of laboratory normal) function. Patients with
leukaemia or solid tumours with >25% bone marrow involvement
were not required to fulfil the above haematological criteria. As
well as baseline haematological and biochemical investigations, a
full physical examination, electrocardiogram, urinalysis and radio-
logical imaging of any tumour sites were performed within 14
days before the first dose of nolatrexed. In addition, for children
with acute leukaemia or solid tumour with likely bone marrow
involvement, a bone marrow aspirate and trephine were required.
Patients were expected to have a life expectancy of at least 9
weeks, and written, informed and witnessed consent was obtained
from all patients or their parents. The study was approved by the
relevant local Ethics Committee. 
Study administration and drug supply 
Patients were entered into the study from 7 participating United
Kingdom Children’s Cancer Study Group (UKCCSG) centres.
Pre-registration (to determine availability of places), registration,
requests for nolatrexed, adverse event reporting and notification of
withdrawal from the study was co-ordinated by the UKCCSG
Data Centre. The study was performed to standards equivalent to
Good Clinical Practice guidelines (CPMP Working Party, 1990),
and data were monitored and managed by the Cancer Research
Campaign Phase I/II Clinical Trials Committee. 
Nolatrexed dihydrochloride was manufactured by Agouron
Pharmaceuticals (La Jolla, California, USA) and was supplied in
5 ml ampoules containing 450 mg of nolatrexed lyophilized powder
for injection, together with 563.5 mg of mannitol which was used as
an inactive caking agent, by the CRC Formulation Unit, Department
of Pharmaceutical Sciences, University of Strathclyde, Glasgow, UK. 
Patient treatment and evaluation 
Nolatrexed was administered by continuous intravenous infusion
via a central line for 5 consecutive days. Anti-emetics were admin-
istered following the first episode of emesis, and were then allowed
on a prophylactic basis. Treatment cycles were repeated every 28
days, provided there was recovery from toxicity. All responding
patients, or those with stable disease, were allowed to continue on
therapy with nolatrexed for up to one year at the discretion of their
physician, unless disease progression was observed. 
Patient review, physical examination, and measurement of the
full blood count and serum concentrations of urea, creatinine, elec-
trolytes, calcium, phosphate, magnesium, glucose, total bilirubin,
total protein, albumin, alanine aminotransferase, alkaline phos-
phatase, were carried out weekly. Patients were evaluable for
response if they received 5 days of nolatrexed, and were evaluable
for toxicity if they survived for at least a further 23 days.
Radiological investigations such as CT, MRI and ultrasonography
were used to evaluate malignant lesions provided that at least one
diameter was equal to or greater than 3 cm. Disease was measured
in accordance with WHO criteria (WHO, 1979). 
Dose escalation 
Nolatrexed doses were based on body surface area, which was calcu-
lated according to the formula recommended by Mosteller (1987) 
Patients were recruited in cohorts of 3 per dose level, and dose-
limiting toxicity was defined on the basis of toxicities observed on
cycle 1 for each patient. No within-patient dose escalations were
allowed. The initial dose level of 480 mg/m2 24 h− 1, which repre-
sented 60% of the adult MTD (Rafi et al, 1998), was chosen as
prolonged dose-limiting myelosuppression and oral mucositis had
been observed in a hevily pre-treated 18-year-old female with
metastatic rhabdomyosarcoma, who had received nolatrexed on a
compassionate use basis at the adult MTD. In addition, plasma
12 EJ Estlin et al
British Journal of Cancer (2001) 84(1), 11–18 © 2001 Cancer Research Campaign
N H2N
HN
OS
CH3
N
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3600deoxyuridine levels were consistently elevated in adult patients
receiving nolatrexed at 480 mg/m2 24 h 1, indicating that systemic
inhibition of the target enzyme was being achieved (Rafi et al, 1995). 
Definition of DLT and MTD 
Dose-limiting toxicity was defined as a Serious Adverse Event that
occurred during the first 28 days after the start of the nolatrexed
infusion. The severity of toxicities were graded according to the
Common Toxicity Criteria (CTC), and toxicity was considered to
be dose limiting as follows: 
Non-haematological DLT 
Any Grade 3 or 4 toxicity, except for Grade 3 nausea and vomiting,
Grade 3 hepatic toxicity which returned to a minimum of Grade 1
within to 28 days of nolatrexed administration, or Grade 3 fever.
For mucositis to be dose limiting, Grade 4 toxicity was required to
persist for at least 7 days. 
Haematological DLT (solid tumours with no or <25% bone
marrow involvement) 
DLT was defined by CTC Grade 3 or 4 neutropenia, or Grade 3
thrombocytopenia lasting at least 7 days, or by Grade 4 thrombo-
cytopenia of any duration. 
Haematological DLT (leukaemia and solid tumours with
>25% bone marrow infiltration) 
DLT was defined by CTC Grade 4 neutropenia or thrombo-
cytopenia with confirmatory bone marrow appearances of tri-
lineage hypoplasia 5 weeks after receiving nolatrexed. DLT was
defined by bone marrow aplasia which persisted for >5 weeks
following the commencement of the nolatrexed cycle, as nadir
neutrophil/platelet counts would not be relevant due to the under-
lying haemopoietic disorder (Ettinger et al, 1993). 
When DLT was encountered in one patient of a cohort of 3, a
maximum of 3 additional patients were treated at that level. If DLT
was not observed with the additional patients, patients were entered
at the next dose level. The MTD was defined as that dose level
immediately below that at which a minimum of 2 patients in a
cohort of 3 to 6 patients experienced DLT. A maximum of 1 out of
6 patients could experience DLT at the MTD dose level. A total of
6 patients were treated at the MTD dose level to fully assess toxi-
city, and this strategy was designed to allow the MTD to be esti-
mated using a minimum number of patients (Korn et al, 1994). 
Pharmacokinetic and pharmacodynamic analyses 
For the measurement of plasma nolatrexed, 3–5 ml blood samples
were taken at 0, 1, 2, 3, 4, 6, 8 and 10 hours following the start of
the 5 day infusion, daily (twice daily if resident in hospital) during
the remainder of the infusion and at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and
24 hours after the end of the infusion. Daily 5 ml blood samples
were also taken for plasma deoxyuridine analyses. All blood
samples were taken into 10 ml lithium-heparin tubes to prevent
coagulation, and the plasma fraction separated within 30 minutes of
collection by centrifugation at 500 g. Plasma samples were then
stored at -20˚C until analysis. Urine samples were also collected,
depending on the age of the child, for the measurement of the
urinary excretion of nolatrexed. A baseline urine sample was
collected, followed by 24 hour collections of urine during each day
of the infusion and for 24 h after completion of the 5 day infusion.
The volume of each 24 hour urine collection was recorded, and a
10 ml aliquot of urine taken and frozen at -20˚C until analysis. 
Plasma and urinary nolatrexed concentrations, and plasma
deoxyuridine concentrations were measured by the high perform-
ance liquid chromatography techniques as described previously
(Rafi et al, 1995). Plasma pharmacokinetics were analysed by non-
model dependent methods, again as previously described. 
RESULTS 
Patient characteristics 
16 patients (7 male and 9 female) with a mean age of 8.5 years
(range 1.5–17) were entered onto the study, and their details are
listed in Table 1. The majority of children suffered from either
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Table 1 Patient characteristics II 
Unique  Dose level Sex Age Underlying disease Evaluable for toxicity Number of
Patient (mg/m2/24 (years) courses 
Number hours) received 
#01 480 F 4 Non-Hodgkins lymphoma No 1 
#02 480 F 14 ALL No 1 
#03 480 M 11 ALL No 1 
#04 640 M 10 AML No 1
#05 640 M 8 ALL Yes 1 
#06 640 F 1 AML No 1 
#07 640 M 6 AML Yes 1 
#08 640 M 4 Neuroblastomab No 1 
#09 640 F 17 Osteogenic sarcoma Yes 2 
#10 640 F 3 Peripheral Neuroectodermal tumour Yes 11 
#11 768 F 6 Rhabdomyosarcomab Yes 2 
#12 768 M 14 ALL No 1a
#13 768 F 4 Wilms’ tumour Yes 1 
#14 768 M 11 ALL Yes 1 
#15 768 F 7 ALL No 1a
#16 768 F 16 ALL Yes 1 
a Indicates that the patient did not complete the 5 day intravenous infusion of nolatrexed. b Indicates disease involving the bone
marrow. multiply relapsed acute lymphoblastic leukaemia (n = 7) or acute
myeloid leukaemia (n = 3). All patients entering the study had
received prior chemotherapy both at initial presentation and for at
least their first relapse; 8 patients had received prior radiotherapy,
7 patients had received prior surgery and 2 patients had received a
prior allogenic bone marrow transplantation. 
Dose escalation and toxicities 
Of the 16 patients who entered the study, 8 completed the first 28
days required for toxicity evaluation. 4 patients (1 with non-
Hodgkins lymphoma, 1 with ALL and 2 with AML) died of
disease progression within the first cycle of therapy. Two patients
with ALL were withdrawn from the study in order to receive alter-
native therapy, 1 patient experienced a Grade 4 anaphylactic reac-
tion to the nolatrexed infusion and 1 patient was withdrawn from
study during the toxicity evaluation period at parental request. Of
the 3 patients who entered at the 480 mg/m2 24 h− 1 dose level, 2
patients with ALL were withdrawn on days 12 and 14, respect-
ively, in order to receive alternative therapy. The third patient at
the first dose level died of overwhelming progression of a Ki-1
positive NHL on day 16. However, no acute toxicities had been
encountered in this patient cohort, and the plasma pharmacoki-
netic findings were in keeping with those in the adult Phase I study
at a comparable dose level (see below). Therefore, since all acute
antiproliferative toxicities were experienced within 14 days for
adults receiving nolatrexed (Rafi et al, 1998), a decision to dose-
escalate to the second dose level of 640 mg/m2 24 h− 1 was made. 
Antiproliferative toxicities were encountered at the second and
third dose levels (Table 2). At the 640 mg/m2 24 h− 1 dose level,
patient #05 experienced Grade 2 oral mucositis from days 2 to 7.
Patient #09 received 2 cycles of therapy with nolatrexed, and
experienced Grade 3 oral mucositis from day 3 to 10 of each cycle,
and Grade 3 thrombocytopenia and Grade 3 neutropenia during
each cycle. At the 768 mg/m2 24 h− 1 dose level, toxicities became
dose limiting. In patient #13, myelosuppression was dose limiting,
with Grade 4 thrombocytopenia observed on day 7, which recov-
ered to Grade 3 by day 9. This patient also experienced dose-
limiting hepatic toxicity, with Grade 4 hyperbilirubinaemia
observed on day 11. The bilirubin remained elevated throughout
the duration of the first cycle. However, this patient was known to
have metastatic disease in the area of the porta hepatis and had
experienced previous liver dysfunction in response to therapy with
actinomycin D. Two patients experienced dose-limiting oral
mucositis. Patient #14 experienced Grade 4 oral mucositis, which
began on day 2, for a duration of 7 days. Patient #16 experienced
Grade 4 oral mucositis, which began on day 5, for a duration of 7
days. Patient #15 had an immediate Grade 4 anaphylactic reaction
to the nolatrexed infusion and was withdrawn from study. 
Patient #10 experienced Grade 3 oral mucositis from days 4 to
7, and Grade 3 neutropenia between day 7 and day 9 during the
first cycle. This patient received 11 courses of therapy with nola-
trexed, and experienced a changing pattern of antiproliferative
toxicity with time. Whereas for the first 5 cycles of
treatment Grade 2/3 mucositis and myelosuppression was encoun-
tered, these toxicites were less marked during latter cycles.
Hyperbilirubinaemia, occurring with a median onset of 13 days
(range 2–21 days) time was observed in 9 children and was dose
limiting in one child. Elevations in hepatic transminases were
reported in 9 patients (median onset of 6 days; range 1–21 days),
but were not dose limiting. 
A wide variety of other adverse events were reported, and these
mainly reflected the poor medical condition of children with
advanced malignancy. 6 children (38%) experienced ≤ Grade 2
nausea and/or vomiting during the period of the nolatrexed infu-
sion, which was easily controlled with standard anti-emetic
therapy. Other reported adverse events included electrolyte distur-
bances, constipation, pyrexia, fever and infection; however, these
were felt to be unrelated to therapy with nolatrexed. The occur-
rence of a rash was reported in 36% of cases, varying from
lymphomatous skin involvement and thrombocytopenic petechiae,
to non-specific erythematous appearances. Renal impairment was
reported in one patient (#12), a 14-year-old male with known
tuberose sclerosis and multiply relapsed ALL. The patient devel-
oped convulsions, drowsiness, fever and plasma biochemical signs
of tumour lysis with an elevated urate (× 2 the upper limit of
normal), phosphate (Grade 2) and creatinine (Grade 2) on the
second day of the nolatrexed infusion. The patient had a known
past medical history of epilepsy, and the biochemical changes
were not sufficient to warrant intervention with dialysis. The
patient died on day 5, and a combination of leukaemia and infec-
tion was thought to be the reason for death. 
Pharmacokinetics 
Plasma nolatrexed concentration-versus-time data were available
for 14 patients. Steady-state plasma concentrations were generally
achieved within 12 hours of the start of the infusion (Figure 2).
Peak plasma levels ranged from 4 µg ml− 1 at 480 mg/m2 24 h− 1 to
20µg ml− 1 at the 768 mg/m2 24 h− 1 dose level, and a 2–3 fold inter-
individual variation in steady-state levels was observed at each
dose level. For patients #9 and #13, there was a tendency for
plasma levels to increase throughout the infusion period,
suggesting saturation of nolatrexed clearance. A marked example
of this apparent saturation was observed in patient #12, where an
incomplete pharmacokinetic analysis was performed as the patient
died on day 5 of the study. In this patient, the plasma nolatrexed
concentrations achieved were the highest in this paediatric popula-
tion; the patient having achieved an AUC of 88 mg ml− 1 min− 1 by
76 hours of an 83-hour infusion. Evidence of non-linearity with
saturation of nolatrexed clearance with increasing dose level may
be indicated by the relative increase in mean AUC. Whereas the
33% increase in nolatrexed dose between dose level one and dose
level two was associated with a 38% increase in mean AUC, the
14 EJ Estlin et al
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Table 2 Significant antiproliferative toxicities encountered following
treatment with nolatrexed 
Maximum CTC Grade 
Dose Number Evaluable Patient Haematological Oral 
level entered for identification mucositis 
(mg/m2 toxicity
24 h 1)( n)
480 3 None None None 
640 7 4 #05 2 
#09 3 3 
#10 3 3 
768 6 4 #13 4 2 
#14 4 
#16 4 20% increase in nolatrexed dose between dose level two and dose
level three was associated with a 60% increase in mean AUC.
Overall, across the three dose levels, a 60% increase in nolatrexed
dose was associated with a 122% increase in mean AUC, and
mean clearance values tended to decrease at the highest dose level. 
The average systemic exposure to nolatrexed increased with
increasing dose level (r2 = 0.4, P < 0.02), although a 2–3 fold inter-
individual variation in AUC was seen at the higher two dose levels
(Figure 3). Nolatrexed was rapidly cleared from the plasma with a
median elimination half-life of 1.9 hours (range 1.2 to 4.6 hours).
Less than 30% of the nolatrexed dose was eliminated as
unchanged drug in the urine (range 13–27%). Pharmacokinetic
analyses are presented in Table 3. 
Responses 
Short-lived oncolytic responses were observed in 2 patients with
ALL. For patient #02, a reduction in the peripheral white cell
count from 51 × 109 l− 1 to 19× 109 l− 1 occurred by the end of the 5
day infusion. For patient #03, a reduction in the peripheral white
cell count from 14 × 109 l− 1 to 7 × 109 l− 1 was observed. However,
both patients were withdrawn from study by day 14 to receive
alternative therapy with methylprednisolone. For a patient with a
peripheral neuroectodermal tumour (patient #10), stable disease
was observed for 11 months. 
Pharmacokinetic/pharmacodynamic relationships 
The pharmacodynamic parameters studied following nolatrexed
administration were antiproliferative toxicity (mucositis and
myelosuppression) and nolatrexed-induced changes in plasma
deoxyuridine concentrations. As shown in Figure 3, whereas no
toxicity was encountered if the nolatrexed AUC was < 45 mg ml− 1
min− 1, Grade 3 or 4 toxicity was observed in all 5 patients who
achieved an AUC of > 60 mg ml− 1 min− 1. There was no relationship
between the occurrence of hyperbilirubinaemia and nolatrexed
dose-level or AUC. 
The effect of nolatrexed administration on plasma UdR concen-
trations was studied in 3 children at each dose level. Plasma UdR
concentrations were elevated within 24 hours of the beginning of
the nolatrexed infusion; however, a 6-fold variation in pretreat-
ment plasma UdR levels was observed within this paediatric popu-
lation. Similarly substantial inter-individual variation in the
magnitude of the UdR elevation was found (Figure 4). As shown
in Figure 4, there was no nolatrexed dose dependency in the eleva-
tion of plasma UdR levels, and no evidence of a relationship
between UdR elevation and antiproliferative toxicity. 
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Figure 2 Representative plasma nolatrexed concentration versus time data
during and following a 5 day intravenous nolatrexed infusion at each dose
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Table 3 Pharmacokinetic parameters for nolatrexed administered by 5-day intravenous infusion 
Dose level  n AUC Volume  of Clearance t1/2 Urine excretion (%) 
(mg/m2 (mg ml 1 min 1) distribution (l/m2 h 1) (hours)
24 h-1) (l/m2)
Mean Range Mean Range Mean Range Mean Range Mean Range 
480 3 36 33–42 9 7–10 4 3.4–4.3 1.6 1.2–1.9 15 14–18 
640 7 50 32–76 14 7–22 4.1 2.3–5.9 2.6 1.4–4.6 15 13–16 
768 4 80 53–125 9 7–12 3.2 1.8–4.3 2.2 1.23–2.8 19 12–27 
Parameters were calculated using model-independent pharmacokinetic analyses as described in methods. DISCUSSION 
This paper describes a Phase I study of nolatrexed, administered as
a 5-day continuous intravenous infusion, in children with
advanced cancer. The primary aims of the study were to determine
the MTD, dose-limiting toxicities and pharmacokinetics of nola-
trexed in children with advanced cancer, together with the charac-
terization of pharmacokinetic–pharmacodynamic relationships. A
secondary aim was to document antitumour efficacy. 
The study was initially designed to be performed solely in chil-
dren with acute leukaemia or solid tumours with >25% bone
marrow involvement. However, this population of patients are both
heavily pre-treated and have multiply drug-resistant end stage
disease. In addition, we had elected to commence recruitment at
480 mg/m2 24 h− 1, and assess the tolerability of nolatrexed in chil-
dren at this dose level, in view of the adult experience of toxicity in
a heavily pretreated 18 year old patient receiving 640 mg/m2 24 h− 1
nolatrexed on compassionate grounds. Therefore, dose-escalation
from the first dose level, which represented 60% of the adult MTD,
was undertaken even though the first 3 patients recruited to the
study did not strictly satisfy the criteria for toxicity evaluation.
However, for all these patients, acute toxicities were not observed
in the first 14 days of follow up, during which time acute toxicity
would be observed in adults receiving nolatrexed (Rafi et al, 1998),
and the plasma pharmacokinetic analyses were in keeping with the
adult Phase I study of nolatrexed. However, of the first 8 patients
who were entered into the study, only 2 satisfied the requirements
for toxicity evaluation, i.e. to remain on study for 28 days without
receiving therapy such as high-dose corticosteroids. Therefore, the
eligibility criteria of the study were broadened to include all chil-
dren with advanced cancer, which improved the rate of subsequent
patient recruitment and successful toxicity evaluation. 
The dose-limiting antiproliferative toxicities of oral mucositis
and myelosuppression observed with nolatrexed in children are in
keeping with the toxicity findings of the adult Phase I study of the
drug when administered as a 5-day intravenous infusion (Rafi et al,
1998). However, the MTD defined by the current study, i.e.
640 mg/m2 24 h− 1, is 80% of the recommended adult Phase II dose
determined by the adult Phase I study. This apparent discrepancy
may reflect the more intensive prior therapy that this paediatric
population had received. Indeed, although it has been recognized
that a wide range in variation of the paediatric versus adult MTD
exists for many antineoplastic agents (Marsoni et al, 1985) which
can reflect differences in the intensity of prior chemotherapy,
and/or physiological differences in renal function, hepatic metabol-
ism and body composition (Balis et al, 1993), there has been a trend
towards a lower paediatric:adult MTD ratio over the past decade,
which illustrates the importance of prior therapy in the relative
tolerance of new anticancer agents (Carlson et al, 1996).
Furthermore, more recent Phase I studies have accrued a second
stratum of less heavily pre-treated children (Blaney et al, 1997). 
As in the adult Phase I study, the onset of oral mucositis
occurred early in the course of therapy with nolatrexed, and was
usually established before the end of the 5-day infusion. Other
toxicities encountered in this paediatric Phase I study, such as
nausea and vomiting, diarrhoea, rash and hepatotoxicity were
similar to those reported in the adult 5-day intravenous Phase I
study (Rafi et al, 1998). However, the focal desquamation of the
hands, feet and scrotal areas observed in the adult study were not
encountered in the present study. For the adult Phase I studies of
nolatrexed administered as 5-day and 10-day intravenous infu-
sions, thrombotic episodes in the vein receiving the nolatrexed
infusion were reported (Creaven et al, 1998; Rafi et al, 1998). This
complication was not recognized in the present paediatric study,
although as in the adult 5- and 10-day studies, nolatrexed was
administered via a central venous catheter. The major toxicities of
oral mucositis and myelosuppression encountered in the present
study are similar to those described in children for other antifolates
such as MTX (Wolfram et al, 1993), trimetrexate (Balis et al,
1987) and piritrexim (Adamson et al, 1990). 
In the adult 5-day intravenous study, a dose-dependent decrease
in nolatrexed clearance was observed, in keeping with saturable
elimination (Rafi et al, 1998). Moreover, at doses ≥ 768 mg/
m2 24 h− 1, there was a tendency for plasma nolatrexed levels to
increase throughout the infusion period. A similar finding was
demonstrated in 3 children in the present study. Indeed, marked
nonlinearity was observed in a patient with tuberose sclerosis and
relapsed ALL, who was treated at the 768 mg/m2 24 h− 1 dose level
in the present study. The reasons for this observation are not
certain; there was no obvious mechanism for a drug interaction,
and the finding may represent abnormally low hepatic metabol-
ism, or reduced renal elimination in the face of impaired renal
function secondary to tumour lysis. Although the mean nolatrexed
AUC increased with successive dose levels in the present study, a
2-to 3-fold inter-individual variation was observed at each dose
level. A similar inter-individual variation in systemic exposure
was found for adults receiving nolatrexed (Rafi et al, 1998), and
pharmacokinetic variability has been recognized for a variety of
anticancer agents in children (Rodman et al, 1993). As with the
adult 5-day intravenous study, increases in nolatrexed AUC were
related to antiproliferative toxicity. Similarly, <30% of nolatrexed
was excreted in the urine. 
Measurement of plasma deoxyuridine concentrations indicated
that systemic inhibition of TS occurred at each dose level in the
present study. This is in keeping with the findings of the study of
nolatrexed administered as a 24-hour infusion in adults (Rafi et al,
1995), where doses of nolatrexed at 480 mg/m2 and above were
associated with elevations of plasma deoxyuridine concentrations.
Moreover, as for the Phase I study of nolatrexed administered as a
5-day continuous infusion in adults (Rafi et al, 1998), there was no
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Figure 4 Plasma deoxyuridine concentrations in children treated with
nolatrexed. Each triplet of bars represents data from an individual patient
course. Data marked with an asterisk (*) were those courses associated with
a Grade 3/4 antiproliferative toxicity. clear relationship between the increase in UdR concentrations and
nolatrexed AUC or antiproliferative toxicity. 
In conclusion, nolatrexed given as a 5-day continuous infusion
in children produces predictable and reversible antiproliferative
toxicities, and plasma biochemical evidence of systemic TS inhibi-
tion. The low rate of completion of toxicity evaluation for children
with acute leukaemia highlights the difficulty of performing single
agent Phase I studies in this patient population. Although antitu-
mour activity with nolatrexed has been demonstrated in Phase II
studies in adults, no objective responses were observed in the
present study. This may not be surprising given the intensity of
previous therapy experienced by this paediatric population. The
further evaluation of this class of anticancer agents in children is
warranted. 
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